References

Wang CH, Pandey S, Sivalingam K, Shibu MA, Kuo WW, Yu-LanYeh, Viswanadha VP, Lin YC, Liao SC, Huang CY (2021) Leech extract: A candidate cardioprotective against hypertension-induced cardiac hypertrophy and fibrosis. J Ethnopharmacol 264:113346. doi: 10.1016/j.jep.2020.113346 PMID: 32896627

Objective: To delineate the molecular mechanisms of medicinal leech extract in the treatment of cardiac hypertrophy and fibrosis, using both in vitro and in vivo assessments.

Summary: Pre-treatment with leech extract significantly reduced angiotensin II (ANG II)-induced cardiac hypertrophy and fibrosis.

Usage: Western blot; PVDF membranes were incubated with Anti-AT-1R.

Related Products: Angiotensin II receptor (AT-1R) Rabbit Polyclonal, affinity-purified (Cat. #AB-N27AP)

Nizari S, Wells JA, Carare RO, Romero IA, Hawkes CA (2021) Loss of cholinergic innervation differentially affects eNOS-mediated blood flow, drainage of Aβ and cerebral amyloid angiopathy in the cortex and hippocampus of adult mice. Acta Neuropathol Commun 9(1):12. doi: 10.1186/s40478-020-01108-z

Summary: In this report, icv administration of mu p75-SAP resulted in significant death of cholinergic neurons and fibres in the medial septum, cortex and hippocampus of C57BL/6 mice. This study supports the importance of the interrelationship between cholinergic innervation and vascular function in the etiology and/or progression of cerebral amyloid angiopathy (CAA) and suggests that combined endothelial nitric oxide synthase (eNOS)/cholinergic therapies may improve the efficiency of Aβ removal from the brain and reduce its deposition as CAA.

Usage: mu p75-SAP (0.596 μg/μl) was injected into the left and right lateral ventricles.

Related Products: mu p75-SAP (Cat. #IT-16)

Lim I, Mitsui R, Kameda M, Sellers DJ, Chess‐Williams R, Hashitani H (2021) Comparative effects of angiotensin II on the contractility of muscularis mucosae and detrusor in the pig urinary bladder. Neurourol Urodyn 40:102-111. doi: 10.1002/nau.24548 PMID: 33074588

Objective: To explore contractile actions of angiotensin II (AT2) on the muscularis mucosae (MM) of the bladder.

Summary: The MM appears to have great sensitivity to AT2, suggesting that MM may be the predominant target of contractile actions induced by AT2 in the bladder.

Usage: Induction of contractions with Anti-AT2R (1 nM – 1 µM). Immunofluorescence (10-100 pM).

Related Products: Angiotensin II receptor (AT-2R) Rabbit Polyclonal, affinity-purified (Cat. #AB-N28AP)

Nelson TS, Taylor BK (2021) Targeting spinal neuropeptide Y1 receptor-expressing interneurons to alleviate chronic pain and itch. Prog Neurobiol 196:101894. doi: 10.1016/j.pneurobio.2020.101894

Summary: Intrathecal administration of NPY-SAP reduced several operant and cognitive measures of Complete Freund’s adjuvant (CFA)-induced allodynia, including responsiveness to cold temperatures, feeding interference, and an escape task, but did not interfere with systemic morphine-induced analgesia. (Wiley et al.) Similar to the spared nerve injury (SNI) model of neuropathic pain, NPY-SAP dose-dependently reduced the development of mechanical allodynia (hindpaw withdrawal response to von Frey filaments), mechanical hyperalgesia (response to blunt pin), and cold allodynia (hindpaw withdrawal response duration to acetone droplet evaporation). (Nelson et al.) Together, these directed lesion studies support the idea that the Y1-IN subpopulation of dorsal horn neurons is necessary for the maintenance of both mechanical and cold modalities of nociceptive transmission in chronic pain states.

Related Products: NPY-SAP (Cat. #IT-28)

See Also:

• Wiley RG et al. Neuropeptide Y receptor-expressing dorsal horn neurons: role in nocifensive reflex responses to heat and formalin. Neuroscience 161:139-147, 2009.
• Nelson TS et al. Facilitation of neuropathic pain by the NPY Y1 receptor-expressing subpopulation of excitatory interneurons in the dorsal horn. Sci Rep 9(1):7248, 2019.

Castiello MC, Bosticardo M, Sacchetti N, Calzoni E, Fontana E, Yamazaki Y, Draghici E, Corsino C, Bortolomai I, Sereni L, Yu HH, Uva P, Palchaudhuri R, Scadden DT, Villa A, Notarangelo LD (2021) Efficacy and safety of anti-CD45-saporin as conditioning agent for RAG deficiency. J Allergy Clin Immunol 147(1):309-320.e6. doi: 10.1016/j.jaci.2020.04.033

Objective: To improve multi-lineage engraftment using non-genotoxic conditioning with Anti-CD45-Saporin.

Summary: Conditioning with Anti-CD45 antibody-drug conjugates may represent a novel and safe conditioning regimen for patients with RAG deficiency and other inborn errors of immunity.

Usage: Intravenous injection of Anti-CD45-SAP (3 mg/kg).

Related Products: Streptavidin-ZAP (Cat. #IT-27)

Chew C, Sengelaub DR (2021) Exercise is neuroprotective on the morphology of somatic motoneurons following the death of neighboring motoneurons via androgen action at the target muscle. Dev Neurobiol 81(1):22-35. doi: 10.1002/dneu.22794

Objective: To determine where the necessary site of androgen action is for exercise-driven neuroprotective effects on induced dendritic atrophy.

Summary: Exercise following neural injury exerts a protective effect on motoneuron dendrites, which acts via androgen receptor action at the target muscle.

Usage: Motoneurons innervating the left vastus medialis (VM) muscle were selectively killed by intramuscular injection of cholera toxin-conjugated saporin (CTB-SAP).

Related Products: CTB-SAP (Cat. #IT-14)

Dezawa S, Nagasaka K, Watanabe Y, Takashima I (2021) Lesions of the nucleus basalis magnocellularis (Meynert) induce enhanced somatosensory responses and tactile hypersensitivity in rats. Exp Neurol 335:113493. doi: 10.1016/j.expneurol.2020.113493

Summary: The authors used 192-IgG-SAP to produce a selective cholinergic lesion in the nucleus basalis of Meynert (NBM) of rats and investigated whether the NBM lesion led to tactile hypersensitivity in the forepaw. Results suggest that neuronal loss in the NBM diminishes acetylcholine actions in the S1, thereby enhancing the cortical representation of sensory stimuli, which may in turn lead to behavioral hypersensitivity.

Usage: The lesion group received injection of 0.3 μL of 192-IgG-SAP into the left nucleus basalis of Meynert (NBM).

Related Products: 192-IgG-SAP (Cat. #IT-01)

Puente BR (2021) Chronic pain in dogs (Dolor crónico en el perro). Zaragoza Spain: Gruppo Asis Biomedia, S. L..

Summary: The author presents a thorough overview of aspects of canine chronic pain. He includes SP-SAP (Substance P-Saporin) as an experimental drug, “its use as an adjuvant analgesic in dogs with bone cancer has been studied,”

Related Products: SP-SAP (Cat. #IT-07)

See Also:

• Brown DC et al. Intrathecal substance p-saporin in the dog: efficacy in bone cancer pain. Anesthesiology 119(5):1178-1185, 2013.

Ma X, Fu S, Yin Y, Wu Y, Wang T, Xu G, Liu M, Xu Y, Tian J, Jiang G (2021) Aberrant functional connectivity of basal forebrain subregions with cholinergic system in short-term and chronic insomnia disorder. J Affect Disord 278:481-487. doi: 10.1016/j.jad.2020.09.103

Summary: Previous animal studies have identified the cholinergic basal forebrain (CBF) as a crucial structure in sleep-wake cycle modulation and lesion or inactivation of the BF has been found to increase delta electroencephalogram activity, disturb behavioral arousal, and reduce sleep. They reference Kaur et al. using 192-IgG-SAP to lesion the CBF to examine the role of these neurons in sleep behavior.

See: Kaur S et al. Effects of ibotenate and 192IgG-saporin lesions of the nucleus basalis magnocellularis/substantia innominata on spontaneous sleep and wake states and on recovery sleep after sleep deprivation in rats. J Neurosci 28:491-504, 2008.

Related Products: 192-IgG-SAP (Cat. #IT-01)

Zhang C, Shen L, Zhu Y, Xu R, Deng Z, Liu X, Ding Y, Wang C, Shi Y, Bei L, Wei D, Thorne RF, Zhang XD, Yu L, Chen S (2021) KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of TRKA independently of its demethylase activity in chronic myelogenous leukemia. Theranostics 11(6):2691-2705. doi: 10.7150/thno.50571 PMID: 33456567

Objective: To identify histone lysine demethylases (KDMs) with altered expression in chronic myelogenous leukemia (CML) and define their contribution to imatinib resistance.

Summary: KDM6A promotes imatinib-resistance in CML cells. The identification of the KDM6A/YY1/TRKA axis as a novel imatinib-resistance mechanism represents an unexplored avenue to overcome tyrosine kinase inhibitor resistance in CML.

Usage: Western blot

Related Products: trkA Rabbit Polyclonal (Cat. #AB-N03)